Philip L Ballard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5242798/publications.pdf

Version: 2024-02-01

471509 377865 1,614 31 17 34 citations h-index g-index papers 36 36 36 1487 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Inhaled Nitric Oxide in Preterm Infants Undergoing Mechanical Ventilation. New England Journal of Medicine, 2006, 355, 343-353.	27.0	463
2	Steroid and Growth Hormone Levels in Premature Infants After Prenatal Betamethasone Therapy to Prevent Respiratory Distress Syndrome. Pediatric Research, 1980, 14, 122-127.	2.3	133
3	GLUCOCORTICOIDS INCREASE PULMONARY S-ADRENERGIC RECEPTORS IN FETAL RABBIT. Endocrinology, 1980, 107, 1646-1648.	2.8	131
4	Differentiation of human pulmonary type II cells in vitro by glucocorticoid plus cAMP. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L940-L951.	2.9	127
5	Corticosteroid Stimulation of Phosphatidylcholine Synthesis in Cultured Fetal Rabbit Lung: Evidence for de Novo Protein Synthesis Mediated by Glucocorticoid Receptors*. Endocrinology, 1983, 112, 829-837.	2.8	88
6	Gene Induction during Differentiation of Human Pulmonary Type II CellsIn Vitro. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 727-737.	2.9	71
7	Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide. Journal of Pediatrics, 2016, 168, 23-29.e4.	1.8	68
8	Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns. Journal of Pediatrics, 2016, 177, 97-102.e2.	1.8	65
9	Plasma Biomarkers of Oxidative Stress: Relationship to Lung Disease and Inhaled Nitric Oxide Therapy in Premature Infants. Pediatrics, 2008, 121, 555-561.	2.1	56
10	Regulated gene expression in cultured type II cells of adult human lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2010, 299, L36-L50.	2.9	50
11	Surfactant Function and Composition in Premature Infants Treated With Inhaled Nitric Oxide. Pediatrics, 2007, 120, 346-353.	2.1	42
12	Race Effects of Inhaled Nitric Oxide in Preterm Infants: An Individual Participant Data Meta-Analysis. Journal of Pediatrics, 2018, 193, 34-39.e2.	1.8	35
13	Antiinflammatory Effects of Budesonide in Human Fetal Lung. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 623-632.	2.9	33
14	Exome sequencing identifies gene variants and networks associated with extreme respiratory outcomes following preterm birth. BMC Genetics, 2018, 19, 94.	2.7	31
15	The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age. Journal of Pediatrics, 2017, 183, 19-25.e2.	1.8	25
16	Ancestry and genetic associations with bronchopulmonary dysplasia in preterm infants. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L858-L869.	2.9	24
17	Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE). Pediatric Research, 2020, 88, 629-636.	2.3	21
18	Surface film formation in vitro by infant and therapeutic surfactants: role of surfactant protein B. Pediatric Research, 2015, 77, 340-346.	2.3	16

#	Article	IF	CITATIONS
19	Maternal Black Race and Persistent Wheezing Illness in Former Extremely Low Gestational Age Newborns: Secondary Analysis of a Randomized Trial. Journal of Pediatrics, 2018, 198, 201-208.e3.	1.8	14
20	Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates. Journal of Pharmaceutical and Biomedical Analysis, 2019, 167, 7-14.	2.8	13
21	Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia. Pediatric Research, 2019, 85, 625-633.	2.3	13
22	Hormonal Influences During Fetal Lung Development. Novartis Foundation Symposium, 1980, 78, 251-274.	1.1	13
23	Inhaled Nitric Oxide Increases Urinary Nitric Oxide Metabolites and Cyclic Guanosine Monophosphate in Premature Infants: Relationship to Pulmonary Outcome. American Journal of Perinatology, 2015, 32, 225-232.	1.4	12
24	Expression of human carcinoembryonic antigen-related cell adhesion molecule 6 and alveolar progenitor cells in normal and injured lungs of transgenic mice. Physiological Reports, 2015, 3, e12657.	1.7	10
25	Surfactant status and respiratory outcome in premature infants receiving late surfactant treatment. Pediatric Research, 2019, 85, 305-311.	2.3	10
26	Thyroid Hormones and Plasma Corticosteroid Binding Globulin Capacity in Fetal and Newborn Lambs*. Endocrinology, 1983, 113, 1197-1200.	2.8	8
27	Expression of Carcinoembryonic Cell Adhesion Molecule 6 and Alveolar Epithelial Cell Markers in Lungs of Human Infants with Chronic Lung Disease. Journal of Histochemistry and Cytochemistry, 2015, 63, 908-921.	2.5	8
28	Blood metabolomics in infants enrolled in a dose escalation pilot trial of budesonide in surfactant. Pediatric Research, 2021, 90, 784-794.	2.3	3
29	Composition and origin of lung fluid proteome in premature infants and relationship to respiratory outcome. PLoS ONE, 2020, 15, e0243168.	2.5	3
30	Claudinâ€18 May Contribute to the Increase of Protein Permeability in Cultured Human Alveolar Epithelial Type II Cells Exposed to Proinflammatory Cytokines. FASEB Journal, 2009, 23, 997.7.	0.5	1
31	The Role of Sulfhydryl Groups in the Binding of Glucocorticoids by Cytoplasmic Receptors of Lung and Other Mammalian Tissues1. Endocrinology, 1977, 100, 1160-1168.	2.8	O